Omeros Corp (OMER) 24.78 $OMER
Will Biotech Fire On All Cylinders In 2015?
Life Sciences Report - at Seeking Alpha - Tue Dec 30, 3:15PM CST
Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early...
MDT: 72.20 (-0.87), PFE: 31.15 (-0.23), CLDX: 18.25 (+0.07), COV: 102.28 (-0.94), INCY: 73.11 (+0.09), NBS: 3.77 (+0.02), BMY: 59.03 (-0.36), OMER: 24.78 (+0.90), CELG: 111.86 (-1.68), ISIS: 61.74 (+0.01), GILD: 94.26 (-1.02), NVAX: 5.93 (+0.11), AZN: 70.38 (-0.31), CEMP: 23.51 (+0.54), FPRX: 27.00 (+0.81)
Autism - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt9w3w/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Sumitomo Dainippon Pharma - Egenix - Novartis - Merz Pharma GmbH & Co - Mitsubishi Tanabe Pharma Corporation - Teva Pharmaceutical Industries - BrainStorm Cell Therapeutics - Avanir Pharmaceuticals - Curemark - Coronado Biosciences - Omeros Corporation - Intra-Cellular Therapies - Cellceutix Corporation - Heptares Therapeutics - Edison Pharmaceuticals - Otsuka Holdings - Reviva Pharmaceuticals - Naurex - Mnemosyne Pharmaceuticals - BioCrea - Saniona - Confluence Pharmaceuticals - MedDay For more information visit http://www.researchandmarkets.com/research/rt...m_pipeline
CNDO: 2.44 (+0.14), TEVA: 57.51 (+0.54), ITCI: 17.65 (-0.35), BCLI: 4.76 (+0.88), OMER: 24.78 (+0.90), NVS: 92.66 (-0.55)
Ischemia Reperfusion Injury - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6pp4ft/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Pharming Group N.V. - BioLineRx, Ltd. - Silence Therapeutics plc - Proteo, Inc. - Scynexis, Inc. - Prolong Pharmaceuticals - Trophos SA - Curatis Pharma GmbH - Alligator Bioscience AB - Opsona Therapeutics Ltd. - PledPharma AB - Zealand Pharma A/S - Omeros Corporation - Bolder Biotechnology, Inc. - Adienne S.r.l. - Genextra S.p.a. - KAEL-GemVax Co., Ltd. - Ischemix - APT Therapeutics, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/6pp4ft/ischemia
OMER: 24.78 (+0.90)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/srj257/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics - Azevan Pharmaceuticals - Catalyst Pharmaceutical Partners - Humanetics Corporation - Intra-Cellular Therapies - Marinus Pharmaceuticals - Nanotherapeutics - Neuralstem - Neurocrine Biosciences - NeuroNascent - Omeros Corporation - Otsuka Holdings - Pfizer - Polleo Pharma - Tonix Pharmaceuticals Holding - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/sr...ttraumatic
NBIX: 22.34 (+0.09), TNXP: 5.84 (-0.20), MRNS: 10.57 (-0.43), CPRX: 2.97 (+0.01), VNDA: 14.32 (-0.19), ITCI: 17.65 (-0.35), OMER: 24.78 (+0.90)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mp6p4/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Alcon Nordic - Allergan - AlphaMab - Amakem - BIOCAD - Boehringer Ingelheim - Charlesson - Circadian Technologies - EyeCyte - EyeGate Pharmaceuticals - F. Hoffmann-La Roche - Genzyme - Icon Bioscience - Iconic Therapeutics - Intas Pharmaceuticals - Kala Pharmaceuticals - Lpath - Mesoblast - Neurotech Pharmaceuticals - Novartis - Ohr Pharmaceutical - Omeros Corporation - Ophthotech - Oxford BioMedica - PanOptica - Pfenex - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Santen Pharmaceutical - Sanwa Kagaku Kenkyusho - Senju Pharmaceutical - TRACON Pharmaceuticals - Tacere Therapeutics - ThromboGenics - iCo Therapeutics - pSivida For more information visit http://www.researchandmarkets.com/research/9m...eovascular
AGN: 212.59 (-0.81), EYEG: (), OHRP: 8.34 (-0.01), REGN: 410.25 (+1.91), OMER: 24.78 (+0.90), NVS: 92.66 (-0.55)
Anxiety Disorders Therapeutic Pipeline Market Review H2 2014 Report at RnRMarketReserach.com
PRWeb - Sun Dec 07, 6:31PM CST
The report "Anxiety Disorders Pipeline Review H2 2014" is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/anxiety-diso...eport.html .
TRVN: 5.98 (+0.01), JNJ: 104.57 (-0.79), LLY: 68.99 (-0.65), CNCE: 13.32 (+0.17), OMER: 24.78 (+0.90)
OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients
PR Newswire - Wed Nov 19, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine protease-2 (MASP-2) program, to inhibit thrombus formation in an ex vivo pathophysiologic system of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. OMS721 is currently in a Phase 2 clinical program evaluating the drug's efficacy in treating TMAs, including aHUS.
OMER: 24.78 (+0.90)
Nasdaq stocks posting largest percentage increases
AP - Tue Nov 18, 12:25PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
RESN: 11.62 (+1.30), AMBA: 50.72 (-1.68), NVEE: 13.00 (unch), TRVN: 5.98 (+0.01), MARK: 4.56 (+0.07), VYFC: 19.81 (+0.05), MSBF: 10.25 (+0.10), MTEX: 26.65 (+0.01), OMER: 24.78 (+0.90)
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Life Sciences Report - Seeking Alpha - Thu Nov 13, 3:24PM CST
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corps? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview...
TTPH: 39.71 (-0.28), JNJ: 104.57 (-0.79), BCRX: 12.16 (+0.05), NAVB: 1.89 (+0.06), CMRX: 40.26 (+2.39), SRPT: 14.47 (-0.05), NBS: 3.77 (+0.02), TKMR: 15.15 (+1.25), GSK: 42.74 (-0.05), CEMP: 23.51 (+0.54), OMER: 24.78 (+0.90)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 6.24 (unch), AGEN: 3.97 (-0.04), NVAX: 5.93 (+0.11), ALXN: 185.03 (+0.09), PPHM: 1.39 (-0.03), THLD: 3.18 (-0.07), GSK: 42.74 (-0.05), OMER: 24.78 (+0.90)
Omeros (OMER) Catches Eye: Stock Jumps 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 7:30AM CST
Omeros Corporation (OMER) was a big mover last session, as the company saw its shares rise almost 9% on the day.
ABAX: 56.83 (-1.10), GWPH: 67.68 (+0.39), OSUR: 10.14 (-0.03), OMER: 24.78 (+0.90)
Omeros ups revenues 9% in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:27AM CST
OMER: 24.78 (+0.90)
Omeros (OMER) CEO Gregory Demopulos on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 10:15PM CST
OMER: 24.78 (+0.90)
Omeros posts 3Q loss
Automated Insights - Mon Nov 10, 5:48PM CST
SEATTLE (AP) _ Omeros Corporation (OMER) on Monday reported a loss of $18.3 million, or 54 cents per share, in its third quarter.
OMER: 24.78 (+0.90)
Omeros beats by $0.05
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:19PM CST
OMER: 24.78 (+0.90)
Omeros Corporation Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 3:02PM CST
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the third quarter of 2014, which include:
OMER: 24.78 (+0.90)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST
HK: 1.78 (+0.05), WWD: 49.23 (-0.64), LLNW: 2.77 (-0.02), FXEN: 1.55 (-0.03), RMTI: 10.28 (+0.52), CZR: 15.69 (-0.47), EGY: 4.56 (unch), ICUI: 81.90 (-1.16), ICEL: 6.43 (+0.18), SAAS: 8.79 (+0.01), DMD: 6.12 (+0.15), NPSP: 35.77 (+0.20), SCLN: 8.76 (+0.09), ATHX: 1.58 (+0.19), CMLS: 4.23 (+0.01), TC: 1.67 (-0.02), ATW: 28.37 (-0.84), CLUB: 5.95 (-0.10), RAX: 46.81 (-0.45), PTLA: 28.32 (-0.24), IPAR: 27.45 (-0.30), ATLS: 31.15 (-0.62), AMBC: 24.50 (-0.14), CUI: 7.45 (+0.12), PDLI: 7.71 (unch), OMER: 24.78 (+0.90), PRAA: 57.93 (-0.57), CARA: 9.97 (+0.02), HALO: 9.65 (+0.25), MODN: 10.62 (-0.09), CALL: 8.12 (+0.29), ASEI: 51.90 (+0.18), HGR: 21.90 (-0.34), ERII: 5.27 (-0.09)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 6.24 (unch), PCYC: 122.26 (-0.32), CLDX: 18.25 (+0.07), INCY: 73.11 (+0.09), BIND: 5.40 (-0.09), CELG: 111.86 (-1.68), OMER: 24.78 (+0.90), VSTM: 9.14 (+0.28), GILD: 94.26 (-1.02), OGXI: 2.29 (+0.06), ANTH: 1.58 (-0.03), NVAX: 5.93 (+0.11)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 212.54 (+2.72), PFE: 31.15 (-0.23), MRK: 56.79 (-0.86), AZN: 70.38 (-0.31), TEVA: 57.51 (+0.54), ITCI: 17.65 (-0.35), ABBV: 65.44 (-0.86), BMY: 59.03 (-0.36), OMER: 24.78 (+0.90)
Global Thrombotic Thrombocytopenic Purpura Therapeutics Pipeline Review 2014 - 6 Companies & 6 Drug Profiles
M2 - Fri Nov 07, 5:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/thbpxv/thrombotic) has announced the addition of the "Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombotic Thrombocytopenic Purpura, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombotic Thrombocytopenic Purpura and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ablynx NV - Kaketsuken K.K. - Glenmark Pharmaceuticals Ltd. - Octapharma AG - Archemix Corp. - Omeros Corporation Drug Profiles - plasma (human) - OMS-721 - caplacizumab - Recombinant Enzyme to Target ADAMTS-13 for Thrombotic Thrombocytopenic Purpura - GBR-600 - ARC-15105 For more information visit http://www.researchandmarkets.com/research/thbpxv/thrombotic
OMER: 24.78 (+0.90)
Will Biotech Fire On All Cylinders In 2015?
Life Sciences Report - at Seeking Alpha - Tue Dec 30, 3:15PM CST
Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early...
MDT: 72.20 (-0.87), PFE: 31.15 (-0.23), CLDX: 18.25 (+0.07), COV: 102.28 (-0.94), INCY: 73.11 (+0.09), NBS: 3.77 (+0.02), BMY: 59.03 (-0.36), OMER: 24.78 (+0.90), CELG: 111.86 (-1.68), ISIS: 61.74 (+0.01), GILD: 94.26 (-1.02), NVAX: 5.93 (+0.11), AZN: 70.38 (-0.31), CEMP: 23.51 (+0.54), FPRX: 27.00 (+0.81)
Autism - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt9w3w/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Sumitomo Dainippon Pharma - Egenix - Novartis - Merz Pharma GmbH & Co - Mitsubishi Tanabe Pharma Corporation - Teva Pharmaceutical Industries - BrainStorm Cell Therapeutics - Avanir Pharmaceuticals - Curemark - Coronado Biosciences - Omeros Corporation - Intra-Cellular Therapies - Cellceutix Corporation - Heptares Therapeutics - Edison Pharmaceuticals - Otsuka Holdings - Reviva Pharmaceuticals - Naurex - Mnemosyne Pharmaceuticals - BioCrea - Saniona - Confluence Pharmaceuticals - MedDay For more information visit http://www.researchandmarkets.com/research/rt...m_pipeline
CNDO: 2.44 (+0.14), TEVA: 57.51 (+0.54), ITCI: 17.65 (-0.35), BCLI: 4.76 (+0.88), OMER: 24.78 (+0.90), NVS: 92.66 (-0.55)
Ischemia Reperfusion Injury - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6pp4ft/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Pharming Group N.V. - BioLineRx, Ltd. - Silence Therapeutics plc - Proteo, Inc. - Scynexis, Inc. - Prolong Pharmaceuticals - Trophos SA - Curatis Pharma GmbH - Alligator Bioscience AB - Opsona Therapeutics Ltd. - PledPharma AB - Zealand Pharma A/S - Omeros Corporation - Bolder Biotechnology, Inc. - Adienne S.r.l. - Genextra S.p.a. - KAEL-GemVax Co., Ltd. - Ischemix - APT Therapeutics, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/6pp4ft/ischemia
OMER: 24.78 (+0.90)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/srj257/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics - Azevan Pharmaceuticals - Catalyst Pharmaceutical Partners - Humanetics Corporation - Intra-Cellular Therapies - Marinus Pharmaceuticals - Nanotherapeutics - Neuralstem - Neurocrine Biosciences - NeuroNascent - Omeros Corporation - Otsuka Holdings - Pfizer - Polleo Pharma - Tonix Pharmaceuticals Holding - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/sr...ttraumatic
NBIX: 22.34 (+0.09), TNXP: 5.84 (-0.20), MRNS: 10.57 (-0.43), CPRX: 2.97 (+0.01), VNDA: 14.32 (-0.19), ITCI: 17.65 (-0.35), OMER: 24.78 (+0.90)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mp6p4/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Alcon Nordic - Allergan - AlphaMab - Amakem - BIOCAD - Boehringer Ingelheim - Charlesson - Circadian Technologies - EyeCyte - EyeGate Pharmaceuticals - F. Hoffmann-La Roche - Genzyme - Icon Bioscience - Iconic Therapeutics - Intas Pharmaceuticals - Kala Pharmaceuticals - Lpath - Mesoblast - Neurotech Pharmaceuticals - Novartis - Ohr Pharmaceutical - Omeros Corporation - Ophthotech - Oxford BioMedica - PanOptica - Pfenex - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Santen Pharmaceutical - Sanwa Kagaku Kenkyusho - Senju Pharmaceutical - TRACON Pharmaceuticals - Tacere Therapeutics - ThromboGenics - iCo Therapeutics - pSivida For more information visit http://www.researchandmarkets.com/research/9m...eovascular
AGN: 212.59 (-0.81), EYEG: (), OHRP: 8.34 (-0.01), REGN: 410.25 (+1.91), OMER: 24.78 (+0.90), NVS: 92.66 (-0.55)
Anxiety Disorders Therapeutic Pipeline Market Review H2 2014 Report at RnRMarketReserach.com
PRWeb - Sun Dec 07, 6:31PM CST
The report "Anxiety Disorders Pipeline Review H2 2014" is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/anxiety-diso...eport.html .
TRVN: 5.98 (+0.01), JNJ: 104.57 (-0.79), LLY: 68.99 (-0.65), CNCE: 13.32 (+0.17), OMER: 24.78 (+0.90)
OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients
PR Newswire - Wed Nov 19, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine protease-2 (MASP-2) program, to inhibit thrombus formation in an ex vivo pathophysiologic system of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. OMS721 is currently in a Phase 2 clinical program evaluating the drug's efficacy in treating TMAs, including aHUS.
OMER: 24.78 (+0.90)
Nasdaq stocks posting largest percentage increases
AP - Tue Nov 18, 12:25PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
RESN: 11.62 (+1.30), AMBA: 50.72 (-1.68), NVEE: 13.00 (unch), TRVN: 5.98 (+0.01), MARK: 4.56 (+0.07), VYFC: 19.81 (+0.05), MSBF: 10.25 (+0.10), MTEX: 26.65 (+0.01), OMER: 24.78 (+0.90)
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Life Sciences Report - Seeking Alpha - Thu Nov 13, 3:24PM CST
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corps? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview...
TTPH: 39.71 (-0.28), JNJ: 104.57 (-0.79), BCRX: 12.16 (+0.05), NAVB: 1.89 (+0.06), CMRX: 40.26 (+2.39), SRPT: 14.47 (-0.05), NBS: 3.77 (+0.02), TKMR: 15.15 (+1.25), GSK: 42.74 (-0.05), CEMP: 23.51 (+0.54), OMER: 24.78 (+0.90)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 6.24 (unch), AGEN: 3.97 (-0.04), NVAX: 5.93 (+0.11), ALXN: 185.03 (+0.09), PPHM: 1.39 (-0.03), THLD: 3.18 (-0.07), GSK: 42.74 (-0.05), OMER: 24.78 (+0.90)
Omeros (OMER) Catches Eye: Stock Jumps 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 7:30AM CST
Omeros Corporation (OMER) was a big mover last session, as the company saw its shares rise almost 9% on the day.
ABAX: 56.83 (-1.10), GWPH: 67.68 (+0.39), OSUR: 10.14 (-0.03), OMER: 24.78 (+0.90)
Omeros ups revenues 9% in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:27AM CST
OMER: 24.78 (+0.90)
Omeros (OMER) CEO Gregory Demopulos on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 10:15PM CST
OMER: 24.78 (+0.90)
Omeros posts 3Q loss
Automated Insights - Mon Nov 10, 5:48PM CST
SEATTLE (AP) _ Omeros Corporation (OMER) on Monday reported a loss of $18.3 million, or 54 cents per share, in its third quarter.
OMER: 24.78 (+0.90)
Omeros beats by $0.05
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:19PM CST
OMER: 24.78 (+0.90)
Omeros Corporation Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 3:02PM CST
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the third quarter of 2014, which include:
OMER: 24.78 (+0.90)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST
HK: 1.78 (+0.05), WWD: 49.23 (-0.64), LLNW: 2.77 (-0.02), FXEN: 1.55 (-0.03), RMTI: 10.28 (+0.52), CZR: 15.69 (-0.47), EGY: 4.56 (unch), ICUI: 81.90 (-1.16), ICEL: 6.43 (+0.18), SAAS: 8.79 (+0.01), DMD: 6.12 (+0.15), NPSP: 35.77 (+0.20), SCLN: 8.76 (+0.09), ATHX: 1.58 (+0.19), CMLS: 4.23 (+0.01), TC: 1.67 (-0.02), ATW: 28.37 (-0.84), CLUB: 5.95 (-0.10), RAX: 46.81 (-0.45), PTLA: 28.32 (-0.24), IPAR: 27.45 (-0.30), ATLS: 31.15 (-0.62), AMBC: 24.50 (-0.14), CUI: 7.45 (+0.12), PDLI: 7.71 (unch), OMER: 24.78 (+0.90), PRAA: 57.93 (-0.57), CARA: 9.97 (+0.02), HALO: 9.65 (+0.25), MODN: 10.62 (-0.09), CALL: 8.12 (+0.29), ASEI: 51.90 (+0.18), HGR: 21.90 (-0.34), ERII: 5.27 (-0.09)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 6.24 (unch), PCYC: 122.26 (-0.32), CLDX: 18.25 (+0.07), INCY: 73.11 (+0.09), BIND: 5.40 (-0.09), CELG: 111.86 (-1.68), OMER: 24.78 (+0.90), VSTM: 9.14 (+0.28), GILD: 94.26 (-1.02), OGXI: 2.29 (+0.06), ANTH: 1.58 (-0.03), NVAX: 5.93 (+0.11)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 212.54 (+2.72), PFE: 31.15 (-0.23), MRK: 56.79 (-0.86), AZN: 70.38 (-0.31), TEVA: 57.51 (+0.54), ITCI: 17.65 (-0.35), ABBV: 65.44 (-0.86), BMY: 59.03 (-0.36), OMER: 24.78 (+0.90)
Global Thrombotic Thrombocytopenic Purpura Therapeutics Pipeline Review 2014 - 6 Companies & 6 Drug Profiles
M2 - Fri Nov 07, 5:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/thbpxv/thrombotic) has announced the addition of the "Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombotic Thrombocytopenic Purpura, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombotic Thrombocytopenic Purpura and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ablynx NV - Kaketsuken K.K. - Glenmark Pharmaceuticals Ltd. - Octapharma AG - Archemix Corp. - Omeros Corporation Drug Profiles - plasma (human) - OMS-721 - caplacizumab - Recombinant Enzyme to Target ADAMTS-13 for Thrombotic Thrombocytopenic Purpura - GBR-600 - ARC-15105 For more information visit http://www.researchandmarkets.com/research/thbpxv/thrombotic
OMER: 24.78 (+0.90)
